Talaris Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mary Fenton

İcra Kurulu Başkanı

US$2.2m

Toplam tazminat

CEO maaş yüzdesi	20.6%
CEO görev süresi	2.6yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.9yrs

Son yönetim güncellemeleri

Recent updates

Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial

Jun 30

Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Mar 23

Talaris Therapeutics EPS beats by $0.49

Jun 14

CEO Tazminat Analizi

Mary Fenton'un ücretlendirmesi Talaris Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$78m
Dec 31 2022	US$2m	US$455k	-US$74m
Sep 30 2022	n/a	n/a	-US$70m
Jun 30 2022	n/a	n/a	-US$64m
Mar 31 2022	n/a	n/a	-US$57m
Dec 31 2021	US$2m	US$340k	-US$48m

Tazminat ve Piyasa: Mary 'ın toplam tazminatı ($USD 2.21M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.40M ).

Tazminat ve Kazançlar: Mary 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mary Fenton (59 yo)

2.6yrs

Görev süresi

US$2,209,223

Tazminat

Ms. Mary Kay Fenton has been Chief Financial Officer at Talaris Therapeutics, Inc. since March 2021 and serves as its Treasurer and has been its Interim CEO and President since May 26, 2023. She had been a...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Suzanne Ildstad	Founder	21.7yrs	US$1.33m	11.88% $ 65.7m
Mark McDade	Independent Director	4.9yrs	US$130.42k	0% $ 0
Geoff MacKay	Independent Director	4.9yrs	US$135.05k	0% $ 0
Sapna Srivastava	Independent Director	2.8yrs	US$137.92k	0% $ 0
Francois Nader	Independent Chairman	4.9yrs	US$175.92k	0.90% $ 5.0m
Sandip Agarwala	Independent Director	4.9yrs	US$130.42k	0% $ 0
Karen Smith	Independent Director	1.4yrs	US$249.58k	0% $ 0
Gaurav Shah	Independent Director	2.8yrs	US$126.92k	0% $ 0

4.9yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TALS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.9 yıldır).

Talaris Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Founder recently sold US$80k worth of stock

Founder notifies of intention to sell stock

Talaris Therapeutics, Inc. Appoints Mary Kay Fenton as President

Founder recently sold US$319k worth of stock

Founder notifies of intention to sell stock

Member of Scientific Advisory Board notifies of intention to sell stock

Recent updates

Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction.

New major risk - Shareholder dilution

New minor risk - Market cap size

Talaris Therapeutics, Inc. Announces Special Dividend

Talaris Therapeutics, Inc. Announces Special Dividend

Price target increased by 39% to US$12.50

Tourmaline Bio, Inc. entered into a definitive agreement to acquire Talaris Therapeutics, Inc. (NasdaqGM:TALS) from shareholders in a reverse merger transaction.

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Founder recently sold US$80k worth of stock

Founder notifies of intention to sell stock

Talaris Therapeutics, Inc. Appoints Mary Kay Fenton as President

Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?

Price target decreased by 17% to US$7.50

Founder recently sold US$319k worth of stock

Price target decreased by 17% to US$7.50

Price target increased by 11% to US$10.00

Founder notifies of intention to sell stock

Price target decreased by 12% to US$8.40

Talaris Therapeutics, Inc. Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?

Price target decreased to US$9.60

Talaris Therapeutics, Inc. Presents Data on Mechanisms of Fcr001 Activity to Induce Immune Tolerance

Price target increased to US$16.75

Talaris Therapeutics Provides Update on Freedom-1 Phase 3 Clinical Trial

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Talaris drops 24% after patient death in late-stage trial for lead asset

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Member of Scientific Advisory Board notifies of intention to sell stock

Talaris Therapeutics GAAP EPS of -$0.44

President recently bought US$167k worth of stock

Independent Chairman recently bought US$500k worth of stock

We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Price target decreased to US$15.25

Talaris Therapeutics Provides Freedom-1 Phase 3 Clinical Update

Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial

Talaris Therapeutics, Inc.(NasdaqGM:TALS) dropped from Russell 2000 Growth Index

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses At American Transplant Congress 2022

Talaris Therapeutics, Inc. Announces Board Changes

Talaris Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

Talaris Therapeutics, Inc Shares New Data on COVID-19 Outcomes Among Living Donor Kidney Transplant Patients Treated in its Phase 2 Trial of Investigational Cell Therapy Product FCR001 (NCT00497926)

Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Talaris Therapeutics, Inc. Presents High-Resolution Analysis of HLS Mismatching in Phase 2 Trial in Living Donor Kidney Transplant

Talaris Therapeutics EPS beats by $0.49

Talaris Therapeutics, Inc. has completed an IPO in the amount of $150.025 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş